Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics

Adv Drug Deliv Rev. 2021 Sep:176:113901. doi: 10.1016/j.addr.2021.113901. Epub 2021 Jul 29.

Abstract

Over the past years, advanced in vitro pulmonary platforms have witnessed exciting developments that are pushing beyond traditional preclinical cell culture methods. Here, we discuss ongoing efforts in bridging the gap between in vivo and in vitro interfaces and identify some of the bioengineering challenges that lie ahead in delivering new generations of human-relevant in vitro pulmonary platforms. Notably, in vitro strategies using foremost lung-on-chips and biocompatible "soft" membranes have focused on platforms that emphasize phenotypical endpoints recapitulating key physiological and cellular functions. We review some of the most recent in vitro studies underlining seminal therapeutic screens and translational applications and open our discussion to promising avenues of pulmonary therapeutic exploration focusing on liposomes. Undeniably, there still remains a recognized trade-off between the physiological and biological complexity of these in vitro lung models and their ability to deliver assays with throughput capabilities. The upcoming years are thus anticipated to see further developments in broadening the applicability of such in vitro systems and accelerating therapeutic exploration for drug discovery and translational medicine in treating respiratory disorders.

Keywords: Aerosols; In vitro; Inhalation therapy; Lung diseases; Lung-on-chips; Preclinical models.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bioengineering
  • Drug Evaluation, Preclinical / methods*
  • Humans
  • Lung*
  • Models, Biological*
  • Respiratory System Agents / therapeutic use*
  • Translational Science, Biomedical

Substances

  • Respiratory System Agents